178 related articles for article (PubMed ID: 28788048)
1. Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors.
Genitsch V; Zlobec I; Seiler R; Thalmann GN; Fleischmann A
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788048
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
3. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
5. MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor.
Genitsch V; Zlobec I; Thalmann GN; Fleischmann A
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):242-7. PubMed ID: 27165976
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Zhang ZF; Bazinet M; Hamdy SM; Reuter VE
J Urol; 1994 Apr; 151(4):914-9. PubMed ID: 8126824
[TBL] [Abstract][Full Text] [Related]
9. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.
Sotomayor P; Godoy A; Smith GJ; Huss WJ
Prostate; 2009 Mar; 69(4):401-10. PubMed ID: 19058139
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.
Jeetle SS; Fisher G; Yang ZH; Stankiewicz E; Møller H; Cooper CS; Cuzick J; Berney DM;
Virchows Arch; 2012 Aug; 461(2):103-7. PubMed ID: 22767265
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
14. Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
Kardoust Parizi M; Iwata T; Kimura S; Janisch F; Abufaraj M; Karakiewicz PI; Enikeev D; Rapoport LM; Hutterer G; Shariat SF
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893781
[TBL] [Abstract][Full Text] [Related]
15. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability.
Gunia S; Albrecht K; Koch S; Herrmann T; Ecke T; Loy V; Linke J; Siegsmund M; May M
World J Urol; 2008 Jun; 26(3):243-50. PubMed ID: 18392627
[TBL] [Abstract][Full Text] [Related]
16. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the Prognostic Significance of Neuroendocrine Differentiation in Gleason Score 7 to 10 Prostate Adenocarcinoma in Patients With Distant Metastasis After Definitive Radiotherapy.
Mankuzhy NP; Almahariq MF; Ye H; Amin M; Stone B; Krauss DJ
Am J Clin Pathol; 2021 May; 155(6):879-886. PubMed ID: 33283224
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine differentiation in prostate cancer.
Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
[TBL] [Abstract][Full Text] [Related]
19. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
20. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
